SCHEMBL19917166

SCHEMBL19917166

Nc1c(NC2CCCCC2)ccnc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT5B Q4FZB7 2/20 0.52
KMT5C Q86Y97 2/20 0.52
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 1/20 0.47
ALDH1A1 P00352 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AOC1 P19801 3/20 0.41
AOC3 Q16853 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CTSK P43235 2/20 0.40
PTGS1 P23219 2/20 0.40
PTGS2 P35354 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 1/20 0.40
LRRK2 Q5S007 1/20 0.40
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28050648 0.82 KMT5B (0.57) KMT5BKMT5CKDM4EGAAALDH1A1
SCHEMBL304560 0.78 NOS2 (0.44) KMT5BKMT5CKDM4EALDH1A1MEN1
SCHEMBL19917187 0.75 KMT2A (0.56) KMT5BKMT5CGAAMAPTALDH1A1
SCHEMBL3784474 0.73 KDM4E (0.59) KMT5BKMT5CKDM4EGAAMAPT
SCHEMBL31720600 0.73 KDM4E (0.59) KMT5BKMT5CKDM4EGAAMAPT
SCHEMBL28908277 0.73 KMT2A (0.53) KMT5BKMT5CGAAMAPTALDH1A1
SCHEMBL11617161 0.72 HPGDS (0.50) KDM4EMAPTMEN1KMT2ACYP2D6
SCHEMBL18520352 0.71 HTT (0.34) KDM4EGAAMAPTALDH1A1L3MBTL1
SCHEMBL6322745 0.71 KMT5B (0.49) KMT5BKMT5CKDM4EMAPTALDH1A1
SCHEMBL23954467 0.70 KDM4E (0.64) KMT5BKMT5CKDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
WO-2018038265-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND PDE7B, PDE3A, PDE7A KMT5B 775/4885KMT5C 438/4885KDM4E 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.